For Which Cancer Types Should I Avoid Maqui Supplement?

Highlights

Nutritional supplements and extracts like Maqui have benefits and are used by cancer patients and those at-genetic risk of cancer. There is limited or hardly any clinical data available for use of nutritional supplements and foods in cancer patients. Generating clinical evidence of efficacy for cancer through a randomized clinical trial is further infeasible due to variations in genetics and cancer chemotherapy treatments across cancer patients. Hence a different and new approach is needed to find out for which cancers you should not take Maqui supplement and why should not take them?

Is it okay to take Maqui extracts or supplements for all cancer indications and any chemotherapy treatment? A common belief but a myth is that everything natural can only be of benefit and do no harm. For example, the use of grapefruit with certain medications is not recommended. Another example is the use of spinach with some blood thinning medications can cause adverse interactions and hence to be avoided. For cancer, nutrition including plant-based foods and supplements can influence outcomes and hence an extremely important decision which needs to be made. Hence NIH-National Cancer Institute has a website for nutrition for cancer care for patients which are generalized recommendations and not personalized for cancer indication and treatments.

A frequently asked question by cancer patients and those at-risk is “What Foods and Nutritional Supplements could be beneficial over others for me?”. “Who should not take an extract or supplement and why?”. Generic guidelines like eating only plant-based-foods or avoiding all sugar or adopting a keto diet is a good start but not actionable and personalized enough.

To find answers to questions on extracts and nutritional supplements and foods requires knowledge of contained active ingredients; genetic mutation prevalence for cancer indication; understanding of underlying cancer biology; chemotherapy treatments and mechanism of actions of active ingredients.

Taking Maqui extracts or nutritional supplements may benefit Primary Non-Small Cell Lung Cancer patients on Erlotinib treatment over Olive nutritional supplements. But Maqui supplements or Maqui extracts offer less benefit if on Radiation treatment for Primary Adamantinoma compared to Peony. Similarly, taking nutritional supplements Maqui may benefit healthy individuals who are at genetic risk of cancer due to mutation of gene ERBB2 over Parsley. But avoid nutritional supplements Maqui when at genetic risk of cancer due to mutation of gene ATM.

The takeaway being – cancer, genomics, treatments and other personalized factors will influence decision making to questions like: Are extracts or nutritional supplements Maqui beneficial and should not be taken? Why should Maqui be not taken? Who should not take Maqui? What are side effects of Maqui with Radiation chemotherapy? What are the benefits of Maqui for cancer? Can Maqui help fight cancer and so on.

Whenever there are changes in chemotherapy treatments or cancer tissue genetics – the nutrition may change and hence needs to be re-evaluated. Do consider factors like cancer indication, ongoing chemotherapy treatments and nutritional supplements, age, gender, weight, height, lifestyle and genetics for personalization of nutrition.

Brief Overview

Use of nutritional supplements – vitamins, herbs, minerals, probiotics, and other specialty categories are increasing. Supplements are high concentrations of active ingredients which are also found in different foods. Difference between supplements and foods being that foods contain more than one active ingredient at much lower concentrations. Every active ingredient in an extract or nutritional supplement or food has a unique mechanism of action which can influence nutrition decisions.

These are some example questions which nutrition planning should help answer for you. Should you take supplements Maqui? Should you take it when at genetic risk of cancer for mutation of gene ERBB2? Should you take it when at genetic risk of cancer for mutation of gene ATM? Should you take it when diagnosed with Primary Adamantinoma? Should you take it when diagnosed with Primary Non-Small Cell Lung Cancer? Should you take it when on Erlotinib treatment? Should you continue taking it if you change your treatment from Erlotinib to Radiation? So a general explanation like – it is organic and plant-based or it increases immunity is not sufficient information for making a decision of use of Maqui extracts and nutritional supplements.

Cancer

Genetic variations across cancer patients can be different and hence no two cancers are alike. The improved availability of “personalized to genetics” chemotherapy treatments and cancer disease monitoring via blood and saliva have been significant factors to improve outcomes. The earlier the lifestyle and treatment intervention – the better the influence on outcome. Genetic testing has the potential to assess cancer risk and susceptibility early. But for at-risk individuals besides regular monitoring in most cases there are no therapeutic treatment intervention options available. After diagnosis with cancer such as Primary Non-Small Cell Lung Cancer or Primary Adamantinoma, the treatments get personalized to tumor genomics and factors like staging of disease, age and gender. During cancer remission (after treatment cycle is complete) – monitoring is used for assessment of any relapse and accordingly decide on next steps. A large majority of cancer patients and those at-risk may take nutritional supplements like Maqui.

So the question is that are all genetic risks and cancer indications to be considered uniformly when making decisions on the use of Maqui extracts or nutritional supplements? Are the biochemical pathway implications of genetic risk for cancer due to mutation of gene ERBB2 the same as due to mutation of gene ATM? Are the implications of Primary Non-Small Cell Lung Cancer the same as Primary Adamantinoma? Is it one and the same if you are on treatment with Radiation or Erlotinib?

Maqui – An Extract or Nutritional Supplement

Maqui is a purple coloured berry which is native to Chile and Argentina. It is considered as a superfruit which is higher in antioxidants than other berries like blackberries, blueberries and raspberries. Maqui is rich in anthocyanins which has immense health benefits. Following are some of the potential benefits of Maqui:

• Possesses anti-inflammatory effect. (Carlos L Cespedes et al, Food Chem Toxicol.,  2017)
• Helps in maintaining healthy heart (R R Watson et al., Minerva Cardioangiol.,  2015) 
• Protective effect on eye (Shin-ichiro Yamashita et al, J Tradit Complement Med. 2019)
• Controls blood sugar (J Hidalgo et al, Panminerva Med. 2014)
• Has anticancer effect (Bo-Wen Lin et al, Br J Pharmacol., 2017, Won-Chul Lim et al, Bioorg Med Chem Lett., 2017)

Maqui supplements contain many active ingredients including Delphinidin at different concentration levels. The molecular pathways which are regulated by Maqui include Growth Factor Signaling, Oxidative Stress and DNA Repair. These biochemical pathways directly or indirectly regulate specific cancer molecular endpoints like growth, spread and death of cancer cells. Because of this biological regulation – for cancer nutrition, the right choice of supplements like Maqui individually or in combination is an important decision to be made. When making decisions on the use of supplement Maqui over other nutritional supplements – do consider all these factors.

Who Should not take Maqui Supplements and Why?

There is no easy way to answer the question “For which cancers should I not chooseMaqui nutritional supplements”. Just like the same chemotherapy treatment does not work across patients, for similar reasons Maqui in comparison with other nutritional supplements may be beneficial or not. Along with which cancer and associated genetics – the ongoing treatments, lifestyle habits, height, weight and food allergies are all factors in deciding if Maqui should be avoided or not and why.

1. Will Maqui Supplements benefit Primary Adamantinoma patients undergoing Radiation treatment?

Primary Adamantinoma is characterized and driven by specific genetic mutations like ARHGAP45, PI4KB and SDSL leading to biochemical pathway changes in Oxidative Stress and Inositol Phosphate Signaling. A cancer treatment like Radiation works through a specific pathway mechanism of action. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach which is effective. In such a condition any food or nutritional supplement which has a contrary effect to the treatment or reduces the overlap should be avoided. As an example, Maqui supplement should not be taken for Primary Adamantinoma along with treatment Radiation. Maqui supplement impacts the biochemical pathway called Oxidative Stress which either promotes drivers of the disease and/or nullifies the treatment effect. Some of the factors which should be considered when choosing nutrition are type of cancer, treatments and supplements being taken currently (if any

2. Will Maqui Supplements benefit Primary Non-Small Cell Lung Cancer Patients undergoing Erlotinib Treatment?

Primary Non-Small Cell Lung Cancer is characterized and driven by specific genetic mutations like CSMD2, LRP2 and CACNA1E leading to biochemical pathway changes in Growth Factor Signaling. A cancer treatment like Erlotinib works through specific pathway mechanisms. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach. In such a condition any food or nutritional supplement which supports treatment action or improves the overlap should be considered. As an example, Maqui supplements should be considered for Primary Non-Small Cell Lung Cancer along with the treatment Erlotinib. Maqui supplement impacts pathways/processes like Growth Factor Signaling which either obstruct drivers of Primary Non-Small Cell Lung Cancer and/or improve Erlotinib treatment effect.

3. What about Maqui Supplements for Healthy Individuals with ATM Mutation associated Genetic Risk?

Different companies offer panels of genes to be tested for assessing genetic risk to different cancers. These panels cover genes associated with cancers of the breast, ovary, uterus, prostate, and gastrointestinal system and others. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant may also guide testing and diagnosis of at-risk relatives. ATM is one of the genes generally available in panels for cancer risk testing.

ATM mutation causes biochemical pathways/processes like DNA Repair to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Maqui should not be taken when the genetic panel identifies mutation of ATM for Chronic Myelomonocytic Leukemia. Maqui impacts pathways/processes like DNA Repair and creates adverse conditions with ATM.

4. What about Maqui Supplements for Healthy Individuals with ERBB2 Mutation associated Genetic Risk?

ERBB2 is one of the genes available in panels for cancer risk testing. ERBB2 mutation causes biochemical pathways/processes like Growth Factor Signaling and PI3K-AKT-MTOR Signaling to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Maqui supplements may be considered when the genetic panel identifies mutations in ERBB2 for Esophageal Adenocarcinoma. Maqui impacts pathways/processes like Growth Factor Signaling and creates a canceling effect in those individuals with ERBB2 mutation.

* Other Factors are also included like BMI, Treatments, Lifestyle Habits

In Conclusion

It is important to remember that cancer chemotherapy treatments and nutrition are never the same for everyone. Food and nutritional supplements like Maqui are chosen by you and can influence outcomes.

“What should I eat?” is a commonly asked question by cancer patients and those at-risk. The answer to this question depends on cancer indication, underlying genetics, current chemotherapy treatments, food allergies, lifestyle information, and food preferences.

The addon.life approach to nutrition personalization uses knowledge of active ingredients contained in foods and nutritional supplements, cancer biology, chemotherapy treatment action and genetic mutation prevalence across cancer indications. addon.life team of clinicians, clinical scientists and engineers are experts in cancer biology focusing only on nutrition personalization for cancer patients and those at-risk.

What food you eat and which supplements you take is a decision you make. Your decision should include consideration of the cancer gene mutations, which cancer, ongoing treatments and supplements, any allergies, lifestyle information, weight, height and habits.

The nutrition planning for cancer from addon is not based on internet searches. It automates the decision making for you based on molecular science implemented by our scientists and software engineers. Irrespective of whether you care to understand the underlying biochemical molecular pathways or not - for nutrition planning for cancer that understanding is needed.

Get started NOW with your nutrition planning by answering questions on the name of cancer, genetic mutations, ongoing treatments and supplements, any allergies, habits, lifestyle, age group and gender.

References

• Delphinidin attenuates pathological cardiac hypertrophy via the AMPK/NOX/MAPK signaling pathway.
• cBioPortal for Cancer Genomics
• Pan-cancer analysis of whole genomes.
• Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
• Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
• Nutraceutical and antioxidant effects of a delphinidin-rich maqui berry extract Delphinol®: a review.
• Delphinidin, an anthocyanidin in pigmented fruits and vegetables, protects human HaCaT keratinocytes and mouse skin against UVB-mediated oxidative stress and apoptosis.
• Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
• cBioPortal for Cancer Genomics
• Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.